Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016622 · ClinicalTrials.gov registry record · Phase 2
Booster Dose Trial
A Phase 2 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT05016622 is a Phase 2 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 106 participants.
The verdict
NCT05016622, a Phase 2 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The goal of this study is to assess the safety and effectiveness of COVID vaccine booster doses in patients with cancer who have not developed an antibody after the U.S. Food and Drug Administration (FDA) Emergency Use Authorized COVID primary vaccination series.
Interventions
- BIOLOGICAL BNT162b2 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2021-08-10 |
| Est. Completion | 2023-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05016622
The ClinicalTrials.gov registry entry for NCT05016622 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BNT162b2 vaccine is the first listed.
NCT05016622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05016622 about?
NCT05016622 is a clinical study titled "Booster Dose Trial". The goal of this study is to assess the safety and effectiveness of COVID vaccine booster doses in patients with cancer who have not developed an antibody after the U.S. Food and Drug Administration (FDA) Emergency Use Authorized COVID primary vaccination series.
What is the current status of trial NCT05016622?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2021-08-10. Estimated completion is 2023-05-21.
What interventions are being tested in trial NCT05016622?
The interventions under investigation include: BNT162b2 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05016622?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.